Market Cap
$151.5M
TARA
Protara Therapeutics, Inc.
$2.70 ▼ -2.17%
Prev close $2.76Market cap$151.5M
12-mo target$25.71 (+852.6%)
16 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TARA right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
50 funds
Inst. Value
$120.3M
Inst. Activity
16 buys / 13 sells
Insider Activity
$0.00 buy / $1.0M sell
Insider Net $
-$1.0M
SEC Reports
7
Press Releases
2
Price chart 30d -31.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 short_volume
Aug 11, 2026 SEC Short Volume: TARA — 58.6% short (0.4M / 0.7M)
Short: 428,722 | Exempt: 10 | TRF Vol: 731,667 | Short Ratio: 58.6% | Off-exchange volume (dark pool
Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven b
PRESS-RELEASE — Impact 4/10
Protara Therapeutics reported Q2 2026 results with a net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2
8-K — Impact 4/10
Jun 30, 2026 Insider
Shefferman Jesse gifted 14,000 shares
CEO and President
Jun 30, 2026 Insider
Shefferman Jesse gifted 7,000 shares
CEO and President
Jun 30, 2026 Insider
Shefferman Jesse gifted 4,000 shares
CEO and President
Jun 30, 2026 Inst.
Qube Research & Technologies — DOUBLED
1,045,516 shares ($4.0M)
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — DOUBLED
701,021 shares ($2.7M)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 20, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| May 14, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Apr 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Aug 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% |
Price targets
Where 7 covering analysts think TARA trades over the next 12 months.
$25.71 +852.6% upside Strong Buy
Current$2.70 Low$20.00 Median$26.00 High$30.00 7 analysts
$20.00$30.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 6 neutral · avg impact 3.6/10.Plus 2 press releases.
NEUTRALPRESS-RELEASE4/10
Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share), widening from a $15.0M loss
Aug 11, 2026
NEUTRAL8-K4/10
Protara Therapeutics reported Q2 2026 results with a net loss of $21.7M ($0.36/share), widening from
Aug 11, 2026
NEUTRAL8-K2/10
Protara Therapeutics disclosed the resignation of Chief Medical Officer Leonardo Viana Nicacio, M.D.
Jun 29, 2026
BEARISHEFFECT5/10
Protara Therapeutics' registration statement on Form S-3 (File No. 333-295862) was declared effectiv
May 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 18, 2026
short_volume
Short Volume: TARA — 58.6% short (0.4M / 0.7M)
Short: 428,722 | Exempt: 10 | TRF Vol: 731,667 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
other
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies f
Aug 11, 2026
earnings
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026
Jul 30, 2026
earnings_calendar
TARA Q2 2026 Earnings Scheduled — 2026-07-30
Jul 10, 2026
short_volume
Short Volume: TARA — 78.1% short (0.4M / 0.6M)
Short: 430,857 | Exempt: 0 | TRF Vol: 552,012 | Short Ratio: 78.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.36 | $-0.38–$-0.34 | -17.1% | -9.7% | 0↑ 3↓ | $0.0B | 6 |
| Next Q | $-0.38 | $-0.41–$-0.35 | 0.9% | -9.5% | 2↑ 3↓ | $0.0B | 6 |
| Current FY | $-1.39 | $-1.46–$-1.31 | -4.0% | -0.4% | 0↑ 5↓ | $0.0B | 6 |
| Next FY | $-1.69 | $-2.25–$-1.13 | -21.4% | -2.9% | 1↑ 3↓ | $0.0B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.363 | — |
| 7d ago | $-0.331 | -0.032 |
| 30d ago | $-0.331 | -0.032 |
| 60d ago | $-0.328 | -0.035 |
| 90d ago | $-0.341 | -0.022 |
Institutional ownership
Which big funds own TARA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $120.3M total value (31,498,810 shares) as of 2026-Q2. Top holders: Jupiter, BlackRock,, MILLENNIUM. Net buying activity: 16 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Jupiter Topco LLC | 4,696,709 | $17.9M | 14.9% | — |
| BlackRock, Inc. | 3,663,499 | $14.0M | 11.6% | ADD +40.9% |
| MILLENNIUM MANAGEMENT LLC | 3,101,166 | $11.8M | 9.8% | DOUBLED +275.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,300,133 | $8.8M | 7.3% | — |
| Blackstone Inc. | 2,265,514 | $8.7M | 7.2% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,326,246 | $5.1M | 4.2% | ADD +44.1% |
| CITADEL ADVISORS LLC | 1,232,365 | $4.7M | 3.9% | — |
| STATE STREET CORP | 1,068,295 | $4.1M | 3.4% | ADD +76.1% |
| Qube Research & Technologies Ltd | 1,045,516 | $4.0M | 3.3% | DOUBLED +490.7% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,026,691 | $3.9M | 3.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | DOUBLED | 177,004 | 1,045,516 | +490.7% | $4.0M |
| MARSHALL WACE, LLP | DOUBLED | 50,731 | 701,021 | +1281.8% | $2.7M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 531,267 | 683,230 | +28.6% | $2.6M |
| NORTHERN TRUST CORP | ADD | 374,852 | 552,306 | +47.3% | $2.1M |
| Point72 Asset Management, L.P. | TRIM | 1,152,714 | 548,932 | -52.4% | $2.1M |
| GOLDMAN SACHS GROUP INC | ADD | 397,981 | 546,227 | +37.2% | $2.1M |
| UBS Group AG | TRIM | 1,402,413 | 456,773 | -67.4% | $1.7M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | DOUBLED | 50,255 | 295,565 | +488.1% | $1.1M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 125,700 | 251,500 | +100.1% | $960.7K |
| Jump Financial, LLC | DOUBLED | 66,779 | 203,100 | +204.1% | $775.8K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 17 transactions. Net -$1.0M — $0.00 bought, $1.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Shefferman Jesse | CEO and President | GIFT | 14,000 | — | — |
| Jun 30, 2026 | Shefferman Jesse | CEO and President | GIFT | 7,000 | — | — |
| Jun 30, 2026 | Shefferman Jesse | CEO and President | GIFT | 4,000 | — | — |
| Jun 30, 2026 | Shefferman Jesse | CEO and President | GIFT | 5,000 | — | — |
| Jun 29, 2026 | Shefferman Jesse | CEO and President | EXERCISE | 215,687 | $1.91 | $412.0K |
| Jun 29, 2026 | Shefferman Jesse | CEO and President | SELL | 215,687 | $4.09 | $882.2K |
| Jun 15, 2026 | BESHAR LUKE M | Director | AWARD | 31,000 | — | — |
| Jun 15, 2026 | GARCEAU ROGER | Director | AWARD | 31,000 | — | — |
| Jun 15, 2026 | Flannelly Barry P | Director | AWARD | 31,000 | — | — |
| Jun 15, 2026 | Solomon Michael Edward | Director | AWARD | 31,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TARA.
Shares short
4,417,095
Settlement Sep 15, 2026
Change vs prior
-0.3%
Semi-monthly cycle
Days to cover
10.3
At avg daily volume
Of shares outstanding
≈7.5%
Estimate — not % of float
All TARA filing & press-release reports (9)
- PRESS-RELEASE reportAug 11, 2026
- 8-K reportAug 11, 2026
- 8-K reportJun 29, 2026
- EFFECT reportMay 26, 2026
- PRESS-RELEASE reportMay 15, 2026
- 8-K reportMay 13, 2026
- PRESS-RELEASE reportMay 13, 2026
- DEFA14A reportApr 28, 2026
- PRESS-RELEASE reportMar 10, 2026